KLCM Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.2M | Sell |
300,430
-19,755
| -6% | -$1.15M | 1.54% | 14 |
|
|
2025
Q4 | $17.3M | Sell |
320,185
-1,683
| -0.5% | -$81K | 1.48% | 12 |
|
|
2025
Q3 | $14.5M | Sell |
321,868
-17,799
| -5% | -$831K | 1.45% | 20 |
|
|
2025
Q2 | $15.7M | Sell |
339,667
-6,620
| -2% | -$325K | 1.67% | 17 |
|
|
2025
Q1 | $21.1M | Sell |
346,287
-186,252
| -35% | -$10.9M | 2.47% | 7 |
|
|
2024
Q4 | $30.1M | Sell |
532,539
-23,043
| -4% | -$1.29M | 3.49% | 4 |
|
|
2024
Q3 | $28.7M | Buy |
555,582
+133,827
| +32% | +$6.28M | 3.41% | 3 |
|
|
2024
Q2 | $17.5M | Buy |
421,755
+31,252
| +8% | +$1.4M | 2.16% | 12 |
|
|
2024
Q1 | $21.2M | Sell |
390,503
-188
| -0% | -$9.58K | 2.72% | 10 |
|
|
2023
Q4 | $20M | Buy |
390,691
+76,740
| +24% | +$4.03M | 3.1% | 6 |
|
|
2023
Q3 | $18.2M | Buy |
313,951
+4,450
| +1% | +$273K | 3.43% | 8 |
|
|
2023
Q2 | $19.8M | Buy |
309,501
+2,617
| +0.9% | +$175K | 3.87% | 5 |
|
|
2023
Q1 | $21.3M | Buy |
306,884
+7,054
| +2% | +$498K | 4.22% | 6 |
|
|
2022
Q4 | $21.6M | Buy |
299,830
+1,190
| +0.4% | +$89.7K | 4.38% | 5 |
|
|
2022
Q3 | $21.2M | Buy |
298,640
+10,138
| +4% | +$735K | 4.98% | 2 |
|
|
2022
Q2 | $22.2M | Sell |
288,502
-52,796
| -15% | -$4.02M | 4.94% | 2 |
|
|
2022
Q1 | $24.9M | Buy |
341,298
+13,807
| +4% | +$927K | 5.28% | 2 |
|
|
2021
Q4 | $20.4M | Buy |
327,491
+9,802
| +3% | +$575K | 4.45% | 7 |
|
|
2021
Q3 | $18.8M | Buy |
317,689
+12,611
| +4% | +$831K | 4.04% | 8 |
|
|
2021
Q2 | $20.4M | Buy |
305,078
+15,287
| +5% | +$997K | 4.51% | 7 |
|
|
2021
Q1 | $18.3M | Buy |
289,791
+8,904
| +3% | +$554K | 4.15% | 6 |
|
|
2020
Q4 | $17.4M | Sell |
280,887
-3,115
| -1% | -$192K | 4.32% | 5 |
|
|
2020
Q3 | $17.1M | Sell |
284,002
-17,180
| -6% | -$1.03M | 4.99% | 2 |
|
|
2020
Q2 | $17.7M | Sell |
301,182
-15,698
| -5% | -$939K | 5.04% | 2 |
|
|
2020
Q1 | $17.7M | Sell |
316,880
-16,685
| -5% | -$1.02M | 5.59% | 2 |
|
|
2019
Q4 | $21.4M | Sell |
333,565
-4,140
| -1% | -$237K | 4.75% | 5 |
|
|
2019
Q3 | $17.1M | Buy |
337,705
+22,535
| +7% | +$1.06M | 4.36% | 9 |
|
|
2019
Q2 | $14.3M | Buy |
315,170
+143,328
| +83% | +$6.68M | 3.52% | 13 |
|
|
2019
Q1 | $8.2M | Buy |
+171,842
| New | +$8.56M | 2.02% | 19 |
|
|
2018
Q1 | – | Sell |
-4,032
| Closed | -$247K | – | 89 |
|
|
2017
Q4 | $247K | Sell |
4,032
-4,000
| -50% | -$250K | 0.06% | 74 |
|
|
2017
Q3 | $512K | Sell |
8,032
-2,100
| -21% | -$123K | 0.13% | 51 |
|
|
2017
Q2 | $565K | Buy |
10,132
+1,732
| +21% | +$94.2K | 0.15% | 45 |
|
|
2017
Q1 | $457K | Buy |
8,400
+665
| +9% | +$36.5K | 0.13% | 47 |
|
|
2016
Q4 | $452K | Buy |
7,735
+400
| +5% | +$21.9K | 0.13% | 45 |
|
|
2016
Q3 | $395K | Buy |
+7,335
| New | +$471K | 0.13% | 49 |
|
Other funds holding BMY
VCM
VPM
KLCM Advisors's BMY Position: Q1 2026 in Review
KLCM Advisors reduced its Bristol-Myers Squibb (BMY) stake by 6.2% in Q1 2026, selling an estimated $1.15M and leaving 300,430 shares worth $18.2M. The position accounts for 1.54% of the portfolio, ranked #14.
KLCM Advisors first reported a position in BMY in Q3 2016 and has held it in 35 quarters since. The position peaked at $30.1M in Q4 2024. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- KLCM Advisors held 300,430 shares of Bristol-Myers Squibb worth $18.2M as of Q1 2026.
- KLCM Advisors sold 19,755 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.15M.
- Bristol-Myers Squibb made up 1.54% of KLCM Advisors's portfolio in Q1 2026, its #14 holding.
- KLCM Advisors first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 35 quarters since.
- KLCM Advisors's Bristol-Myers Squibb position peaked at $30.1M in Q4 2024.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on KLCM Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.